亨利香恩服务获多家机构上调目标价，最高至96美元

Group 1 - Multiple Wall Street firms have updated their investment ratings and target prices for Henry Schein, Inc. (HSIC.OQ) as of February 26, 2026 [1] - Morgan Stanley analyst Erin Wright maintains a sell rating, raising the target price from $58 to $61 [1] - JPMorgan analyst John Stansel maintains a buy rating, increasing the target price from $78 to $92 [1] - Bank of America analyst Allen Lutz keeps a buy rating, raising the target price from $87 to $96 [1] - UBS analyst Kevin Caliendo maintains a hold rating, increasing the target price from $79 to $87 [1] - Mizuho Securities analyst Steven Valiquette maintains a hold rating, raising the target price from $81 to $88 [1] - Leerink Partners analyst Michael Cherny maintains a hold rating with a target price of $87 [1] Group 2 - As of February 26, 2026, Henry Schein, Inc. (HSIC.OQ) has a latest stock price of $81.47, down 0.54% on that day [2] - The stock has increased by 6.08% over the past five days, with a total market capitalization of approximately $9.591 billion [2] - The medical sales sector rose by 1.05% on the same day, while the Dow Jones index increased by 0.03% and the Nasdaq decreased by 1.18% [2]